Pfizer (PFE) Stock Forecast & Price Target

$28.45

+0.11 (+0.39%)

(As of 12:57 PM ET)

Pfizer - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 15 Analyst Ratings

Sell
0

Hold
8

Buy
7

Based on 15 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 8 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for PFE.

Consensus Price Target

$34.54
21.40% Upside

According to the 15 analysts' twelve-month price targets for Pfizer, the average price target is $34.54. The highest price target for PFE is $45.00, while the lowest price target for PFE is $29.00. The average price target represents a forecasted upside of 21.40% from the current price of $28.45.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

PFE Analyst Ratings Over Time

Type	Current Forecast 10/5/23 to 10/4/24	1 Month Ago 9/5/23 to 9/4/24	3 Months Ago 7/7/23 to 7/6/24	1 Year Ago 10/5/22 to 10/5/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	11 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$34.54	$34.54	$35.54	$46.18
Forecasted Upside	21.40% Upside	21.70% Upside	26.70% Upside	37.96% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

Who are Nvidia’s New Silent Partners? (Ad)

Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.

I call these Nvidia’s “Silent Partners.”

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.53	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	21.83% Upside	850.33% Upside	7.73% Upside
News Sentiment Rating	Neutral News See Recent PFE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/3/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$45.00 ➝ $45.00	+58.84%
8/7/2024	Daiwa America 0 of 5 stars	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
8/7/2024	Daiwa Capital Markets 1 of 5 stars		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$30.00 ➝ $31.00	+0.23%
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
5/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $29.00	+4.28%
5/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $36.00	+30.62%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/23/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$36.00	+30.67%
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.00	+7.67%
12/14/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$42.00 ➝ $36.00	+37.35%
10/16/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$42.00 ➝ $35.00	+3.80%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%
10/16/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$38.00 ➝ $39.00	+21.46%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+38.66%
6/29/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$47.00 ➝ $40.00	+10.22%
4/21/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $45.00	+12.92%
2/7/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$40.00	-8.24%
2/1/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$49.00 ➝ $48.00	+8.70%
2/1/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $46.00	+4.17%
12/13/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Chris Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$47.00 ➝ $60.00	+15.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:11 PM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 30, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

Pfizer Inc. reported earnings per share of $0.60 for the quarter, surpassing analysts' estimates by $0.14. This indicates strong financial performance and potential for growth.
The company had revenue of $13.28 billion for the quarter, higher than analysts' expectations of $12.96 billion, showcasing robust revenue generation.
Institutional investors, including hedge funds, have been increasing their stakes in Pfizer Inc., indicating confidence in the company's future prospects.
Pfizer Inc. has a positive return on equity of 8.42%, demonstrating efficient utilization of shareholder equity to generate profits.
With a diverse portfolio of biopharmaceutical products marketed globally, Pfizer Inc. has a strong presence in key markets, providing stability and potential for expansion.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

Pfizer Inc.'s net margin was negative at -4.66%, indicating challenges in controlling costs and maintaining profitability.
The company's payout ratio is -2,799.53%, which suggests that the dividend payments may not be sustainable based on current earnings.
While revenue increased year-over-year, the growth rate of 2.1% may be considered modest, potentially signaling slower expansion compared to competitors.
Stock price fluctuations in the biopharmaceutical sector can be volatile, leading to potential risks for investors seeking stable returns.
Market competition and regulatory uncertainties in the pharmaceutical industry could impact Pfizer Inc.'s future product development and market share.

PFE Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $34.54, with a high forecast of $45.00 and a low forecast of $29.00.
: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 8 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PFE shares.
: According to analysts, Pfizer's stock has a predicted upside of 21.40% based on their 12-month stock forecasts.
: Over the previous 90 days, Pfizer's stock had 2 upgrades by analysts.
: Pfizer has been rated by research analysts at Barclays, Cantor Fitzgerald, Daiwa America, Daiwa Capital Markets, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Pfizer less than other "medical" companies. The consensus rating score for Pfizer is 2.53 while the average consensus rating score for "medical" companies is 2.78. Learn more on how PFE compares to other companies.